Please assess the completion status of the following clinical trial:

Trial Title: A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals diagnosed with Idiopathic Pulmonary Fibrosis~2. Chronic cough \> 8 weeks.~3. Daytime cough severity score ≥ 4 on Cough Severity Numerical Rating Scale at screening~Exclusion Criteria:~1. The following conditions are excluded:~   1. Interstitial lung disease (ILD) known to be caused by domestic and occupational environmental exposures.~  2. Interstitial lung disease (ILD) known to be caused by connective tissue disease.~  3. Interstitial lung disease (ILD) known to be caused by drug related toxicity.~      2. Currently on continuous oxygen therapy.~      3. History of substance abuse that, as determined by the Investigator, may interfere with the conduct of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NAL ER then placebo (Type: EXPERIMENTAL): Participants will receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period, followed by a 2 week washout. They will then receive Placebo tablet (matching NAL ER BID) for 3 weeks.
- Placebo then NAL ER (Type: EXPERIMENTAL): Participants will receive Placebo tablet (matching NAL ER BID) for 3 weeks, followed by a 2 week washout. They will then receive NAL ER 27 mg QD, 27 mg BID, 54 mg BID, 108 mg BID, 162 mg BID over a 3 week period .

Based on this trial design, predict the completion outcome and termination type (if applicable).